非西他滨 | 69123-90-6

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 非西他滨
• 中文别名: 4-氨基-1-(2-脱氧-2-氟-β-D-阿糖胞苷)-5-碘-2(1H)-嘧啶酮；4-氨基-1-[(2R,3S,4R,5R)-3-氟-4-羟基-5-(羟甲基)氧杂环戊-2-基]-5-碘嘧啶-2-酮
• 英文名称: 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-4-imino-5-iodo-3,4-dihydro-1H-pyrimidin-2-one
• 英文别名: Fiacitabine；4-amino-1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one
• CAS: 69123-90-6
• 化学式: C₉H₁₁FIN₃O₄
• 分子量: 371.107
• InChiKey: GIMSJJHKKXRFGV-BYPJNBLXSA-N

物化性质

• 沸点：
  524.6±60.0 °C(Predicted)
• 密度：
  2.44±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥ 37 mg/mL（99.70 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

制备方法与用途

生物活性

Fiacitabine（NSC 382097；FIAC；FOAC）是一种选择性的HSV DNA复制抑制剂，对HSV1和HSV2的IC50分别为2.5 nM和12.6 nM。

用途

非西他滨(Fiacitabine, FIAC) 是一种嘧啶核苷类似物，能够有效对抗多种疱疹病毒。在体内，它会被转化为三磷酸形式，并抑制病毒DNA聚合酶的活性。目前，非西他滨已被用于研究治疗HIV感染和巨细胞病毒感染的试验中。

生产方法

以2-脱氧-2-氟-三苯甲酰基-α-D-阿拉伯呋喃糖为原料，在常温条件下经过溴化氢醋酸溶液溴化得到2-脱氧-2-氟-三苯甲酰基-α-D-溴化阿拉伯呋喃糖；再以胞嘧啶为原料进行碘化，Bz-保护后得到-(5-碘-2-氧代-1,2-二氢嘧啶-4-基)苯甲酰胺。最后通过中间体和反应后的脱保护步骤合成非西他滨。这条合成路线不仅使用廉价的原料，而且反应步骤较少、选择性高，总收率高达43%。

反应信息

• 作为反应物：
  描述：

  非西他滨 在 palladium on activated charcoal 吡啶 、 ammonium hydroxide 、 偶氮二异丁腈 、 氢气 、 三正丁基氢锡 、 sodium methylate 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 25.0 ℃ 、137.9 kPa 条件下， 反应 6.5h， 生成 1-(2,3-二脱氧-2-氟呋喃戊糖基)胞嘧啶
  参考文献：
  名称：

  Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC)

  摘要：

  1-(3-Azido-2,3-dideoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (6, F-AZT) and 1-(2,3-dideoxy-2-fluoro-beta-D-threopentofuranosyl)cytosine (12, F-DDC) were synthesized from the potent antiherpes virus nucleosides 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (1, FMAU) and 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) in the hope that introduction of a 2-"up"-fluoro substituent might potentiate the anti-HIV activity of AZT and DDC. FMAU (1) was converted in three steps into 2,3'-anhydro-1-(2-fluoro-2-deoxy-5-O-trityl-beta-D-lyxofuranosyl)thymine (4), which when treated with NaN3 followed by detritylation afforded 6. F-DDC was prepared by two methods. Tritylation of FIAC followed by treatment of the product with thiocarbonyldimidazole afforded the 5'-O-trityl-3'-O-(imidazolyl)thiocarbonyl nucleoside 9. Upon radical reduction of 9 with Bu3SnH and AIBN, 5'-O-trityl-DDC 10 was obtained. Compound 10 was detritylated to give 12, which (when obtained by this procedure) resisted crystallization, but the diacetate 12' was obtained in crystalline form. Alternatively, FAC (14) was converted into N4,O5'-dibenzoyl derivative 15, which was treated with thiocarbonyldiimidazole. Reduction of 16 with Bu3SnH/AIBN followed by debenzoylation afforded 12, which was obtained in crystalline form. F-AZT did not exhibit any significant activity against the human immunodeficiency virus (HIV) in vitro. F-DDC, however, showed activity against HIV-1, but the therapeutic index is much inferior to that of AZT.

  DOI：

  10.1021/jm00170a016
• 作为产物：
  描述：

  1,3,5-三苯甲酰基-D-呋喃核糖 在 甲醇 、 二乙胺基三氟化硫 、 氨 、 氢溴酸 、 溶剂黄146 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 96.0h， 生成 非西他滨
  参考文献：
  名称：

  Synthesis of DNA oligos containing 2′-deoxy-2′-fluoro-d-arabinofuranosyl-5-carboxylcytosine as hTDG inhibitor

  摘要：

  As an important step of the active demethylation of 5-methylcytosine (5mC), human thymine DNA glycosylase (hTDG) efficiently excises 5-carboxylcytosine (5caC) from double-stranded DNA (dsDNA). Here, we present synthesis of DNA oligos containing a 2'-deoxy-2'-fluoro-D- arabinofuranosyl-5-carboxylcytidine (F-5caC) modification that act as hTDG inhibitors. The glycosylase activity assay showed that F-5caC oligos were resistant to excision by the hTDG catalytic domain (hTDG(cat), residues 111-308) and they could inhibit the excision of DNA oligos containing 5caC. The electrophoretic mobility shift assay confirmed that DNA oligos containing F-5caC could bind well with unmodified hTDG(cat) to form a stable complex, which makes it possible to obtain the crystal structure of the complex to reveal details on how hTDG(cat) recognizes the DNA substrate. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.04.031

文献信息

• Immunosuppressive effects of pteridine derivatives
  申请人：——

  公开号：US20040077859A1

  公开（公告）日：2004-04-22

  This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.

  这项发明涉及一组三取代和四取代的嘌呤衍生物，它们的药用盐、N-氧化物、溶剂化物、二氢和四氢衍生物及对映异构体，具有意想不到的、令人满意的药理性质，尤其是作为高度活性的免疫抑制剂，因此可用于治疗移植排斥反应和/或治疗某些炎症性疾病。这些化合物还用于预防或治疗心血管疾病、过敏性疾病、中枢神经系统疾病和细胞增殖紊乱。
• Nucleotide mimics and their prodrugs
  申请人：——

  公开号：US20040059104A1

  公开（公告）日：2004-03-25

  The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

  本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物，其中包含二磷酸或三磷酸基团模拟物，以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物，以药学上可接受的盐、药学上可接受的前药或药物配方的形式，可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物，可选地与其他药理活性剂结合。
• [EN] TRICYCLIC INHIBITORS OF INFLUENZA VIRUS ENDONUCLEASE<br/>[FR] INHIBITEURS TRICYCLIQUES DE L'ENDONUCLÉASE DU VIRUS DE LA GRIPPE
  申请人：WEBB THOMAS R

  公开号：WO2021195278A1

  公开（公告）日：2021-09-30

  The present disclosure is concerned with 9-hydroxy-6-(pyrrolidin-2-yl)-3,4-dihydro-2H-pyrazino[ 1,2-c]pyrimidine- 1, 8-dione compounds for the treatment of various viral infections such as, for example, influenza virus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及用于治疗各种病毒感染的9-羟基-6-(吡咯啉-2-基)-3,4-二氢-2H-吡嗪并[1,2-c]嘧啶-1,8-二酮化合物，例如流感病毒。本摘要旨在作为在特定领域搜索的扫描工具，并不意在限制本发明。
• Methods and compositions for treating pain
  申请人：Moran M. Magdalene

  公开号：US20070219222A1

  公开（公告）日：2007-09-20

  The present application relates to compounds and methods for treating pain, incontinence and other conditions.

  本申请涉及化合物和治疗疼痛、失禁和其他疾病的方法。
• [EN] 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS<br/>[FR] PYRIDO(3,2-D)PYRIMIDINES TRISUBSTITUÉES EN POSITION 2,4,6 UTILES POUR TRAITER DES INFECTIONS VIRALES
  申请人：GILEAD SCIENCES INC

  公开号：WO2010002998A1

  公开（公告）日：2010-01-07

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formuia (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  Pyrido(3,2-d)pyrimidine衍生物由结构式(Ia)表示：其中，R1、R2和R3在此处定义，其药用可接受的盐、立体化学异构体形式、N-氧化物、溶剂合物及其前药，用于治疗丙型肝炎。